5 results
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
To describe criteria on CLE-imaging of different entities (thoracic wall/ pleura/ fibrosis/ mediastinum) compared to histology.
Primary objective: Determine whether treatment with a PI3K inhibitor (BYL719 or buparlisib) plus letrozole leads to an increase in pathologic response compared to treatment with placebo plus letrozole in patients with hormone receptor-positive HER2-…
To identify and define characteristics of healthy lymph nodes and lymph nodes involved in different pulmonal diseases (lungcancer and sarcoidosis)
To establish in vivo CLE characteristics of Upper Urinary Tract Urothelial Carcinoma